The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States.
Open accessAbstract
OBJECTIVES: The purpose of this study was to assess atherosclerotic cardiovascular disease (ASCVD) prevalence, antidiabetes medication usage and physician specialty encounters among individuals with type 2 diabetes mellitus (T2DM) in the United States during 2015. DESIGN: Retrospective, cross-sectional analysis. PATIENTS: Adults with T2DM in a large US administrative claims database. Patients were divided into ASCVD and non-ASCVD groups. Subgroup analyses were conducted for three age groups (18-44, 45-64 and 65+ years). RESULTS: Of 1 202 596 patients with T2DM, 45.2% had established ASCVD. About 40% of T2DM patients with ASCVD had visited a cardiologist during 2015, compared to 11% in the non-ASCVD group. The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) was low overall (<12%), and even lower in the ASCVD group (<9%). The prevalence of ASCVD was 15%, 36% and 71% in the 18-44, 45-64 and 65+ year age groups, respectively. GLP-1RA and SGLT-2i use was ≤5% in the 65+ subgroup, regardless of ASCVD status. CONCLUSIONS: These real-world data showed a high prevalence of ASCVD among T2DM patients, and confirmed, as a baseline assessment, low use of GLP-1RAs and SGLT-2is in these at-risk patients prior to the 2017 American Diabetes Association guidelines recommending use of agents with proven cardiovascular benefits.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Diabetes itself confers independent ASCVD risk, and among people with diabetes, all major cardiovascular risk factors, including hypertension, hyperlipidemia, and obesity, are clustered and common.
“Diabetes itself confers independent ASCVD risk, and among people with diabetes, all major cardiovascular risk factors, including hypertension, hyperlipidemia, and obesity, are clustered and common (2).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [2]
The Results (Study population; Table 3, page unavailable) show that hypertension and dyslipidemia were common among patients with type 2 diabetes, and the Abstract Results report that 45.2% had established ASCVD. The cited passages do not establish that diabetes independently confers ASCVD risk, or report obesity or the joint clustering of all three risk factors. (LLM, conf=0.88)
Experimental — accuracy not yet measuredDiabetes itself confers independent ASCVD risk.
“Diabetes itself confers independent ASCVD risk, and among people with diabetes, all major cardiovascular risk factors, including hypertension, hyperlipidemia, and obesity, are clustered and common (2).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [2]
The Results (Study population and Subgroup analysis by age category; page unavailable) show that hypertension and dyslipidemia were common among patients with type 2 diabetes, and the Discussion reports that 45.2% had ASCVD. The paper does not establish that diabetes independently confers ASCVD risk or report obesity as a common, clustered risk factor. (LLM, conf=0.86)
Experimental — accuracy not yet measuredAmong people with diabetes, all major cardiovascular risk factors, including hypertension, hyperlipidemia, and obesity, are clustered and common.
“among people with diabetes, all major cardiovascular risk factors, including hypertension, hyperlipidemia, and obesity, are clustered and common (2).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [2]
The Results (Study population, Table 1; page unavailable) report that hypertension (79.1%) and dyslipidemia (77.8%) were common in the studied US population with type 2 diabetes. Our copy does not report obesity prevalence or establish that these risk factors cluster in the same individuals, so it does not support the claim about all three factors being clustered and common. (LLM, conf=0.87)
Experimental — accuracy not yet measuredGLP-1RAs are underused in eligible patients, particularly by cardiologists.
“Despite these findings, GLP-1RAs are underused in eligible patients, particularly by cardiologists.”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742 · see citing works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · see citing works
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · see citing works
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · see citing works
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · see citing works
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · see citing works
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · see citing works
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · see citing works
Young, B. A., Lin, E. H. B., Korff, M. V., Simon, G., Ciechanowski, P. S., Ludman, E. J., Everson‐Stewart, S., Kinder, L. S., Oliver, M. M., Boyko, E. J., et al. (2008) · PubMed · Cited by 606 · see citing works
Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
Iglay, K., Hannachi, H., Joseph Howie, P., Xu, J., Li, X., Engel, S. S., Moore, L. M., & Rajpathak, S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1168291 · Cited by 511 · see citing works
9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
(2017) · Diabetes Care · doi:10.2337/dc18-s009 · Cited by 490 · see citing works
9. Cardiovascular Disease and Risk Management
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s012 · Cited by 223 · see citing works
Gerstein, H., Colhoun, H., Dagenais, G., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riddle, M., Rydén, L., Xavier, D., et al. (2018) · Diabetes, obesity and metabolism · doi:10.1111/dom.13028 · Cited by 179 · see citing works
Pantalone, K. M., Hobbs, T. M., Wells, B. J., Kong, S. X., Kattan, M. W., Bouchard, J. R., Yu, C., Sakurada, B., Milinovich, A., Weng, W., et al. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000093 · Cited by 132 · see citing works
Pantalone, K. M., Misra‐Hebert, A. D., Hobbs, T. M., Ji, X., Kong, S. X., Milinovich, A., Weng, W., Bauman, J. M., Ganguly, R., Burguera, B. G., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0699-7 · Cited by 51 · see citing works
Weng, W., Liang, Y. M., Kimball, E. S., Hobbs, T. M., Kong, S. X., Sakurada, B., & Bouchard, J. R. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.043 · Cited by 34 · see citing works
Flagged first, then by citations
1 of the 20 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [20]Eli Lilly and Company. Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes. 2018 [Press release, November 5, 2018]. https://investor.lilly.com/node/39796/pdf. Accessed December 11, 2018.
Cited by
Sorted by citations
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300 · see citing works
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800 · see citing works
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,206 · see citing works
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339 · see citing works
Mosenzon, O., Alguwaihes, A. M., Leon, J. L. A., Bayram, F., Darmon, P., Davis, T. M. E., Dieuzeide, G., Eriksen, K. T., Hong, T., Kaltoft, M. S., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01344-0 · Cited by 249 · see citing works
Adhikari, R., Jha, K., Dardari, Z., Heyward, J., Blumenthal, R. S., Eckel, R. H., Alexander, G. C., & Blaha, M. J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023811 · Cited by 166 · see citing works
Siam, N. H., Snigdha, N. N., Tabasumma, N., & Parvin, I. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2512436 · Cited by 162 · see citing works
Honigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127 · see citing works
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107 · see citing works
Strain, W. D., Frenkel, O., James, M. A., Leiter, L. A., Rasmussen, S., Rothwell, P. M., Sejersten Ripa, M., Truelsen, T. C., & Husain, M. (2022) · Stroke · doi:10.1161/strokeaha.121.037775 · Cited by 93 · see citing works
Nelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.48030 · Cited by 78 · see citing works
Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
Limonte, C. P., Hall, Y. N., Trikudanathan, S., Tuttle, K. R., Hirsch, I. B., de Boer, I. H., & Zelnick, L. R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108204 · Cited by 58 · see citing works
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Shin, J., Xu, Y., Chang, A. R., Carrero, J. J., Flaherty, C. M., Mukhopadhyay, A., Inker, L. A., Blecker, S., Horwitz, L. I., & Grams, M. E. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.057 · Cited by 54 · see citing works
King, A., Tan, X., Dhopeshwarkar, N., Bohn, R. L., Dea, K., Leonard, C. E., & de Havenon, A. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004431 · Cited by 50 · see citing works
Thomas, M. B., MAGWIRE, M. L., GOSCH, K. L., Sammour, Y. M., Mehta, R., O’Keefe, J. H., Nassif, M. E., & Kosiborod, M. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007682 · Cited by 47 · see citing works
Mata‐Cases, M., Franch‐Nadal, J., Real, J., Vlacho, B., Gómez‐García, A., & Mauricio, D. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.02.003 · Cited by 39 · see citing works
Nair, R., Mody, R., Yu, M. B., Cowburn, S., Кониг, М., & PREWITT, T. G. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01320-1 · Cited by 36 · see citing works
Yaseen, A., & Lahiri, S. W. (2023) · Clinical Diabetes · doi:10.2337/cd22-0100 · Cited by 29 · see citing works
Mahé, G., Aboyans, V., Cosson, E., Mohammedi, K., Sarlon-Bartoli, G., Lanéelle, D., Mirault, T., & Darmon, P. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02325-9 · Cited by 30 · see citing works
Korayem, G. B., Alshaya, O. A., Alghamdi, A. A., ALANAZI, S., Almutib, R. T., Alsaileek, M., Alrashidi, A., Aldosari, N., Sheraim, N. B., Yami, M. S. A., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1031306 · Cited by 25 · see citing works
Mittman, B. G., Le, P., Payne, J. Y., Ayers, G. T., & Rothberg, M. B. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2303413 · Cited by 24 · see citing works
Weng, W., Tian, Y., Kong, S. X., Ganguly, R., Hersloev, M., Brett, J., & Hobbs, T. M. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-019-0090-y · Cited by 24 · see citing works
Devineni, D., Akbarpour, M., Gong, Y., & Wong, N. D. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07403-2 · Cited by 22 · see citing works
Foresta, A., Succurro, E., Baviera, M., Macaluso, G., Fernandez, M. L. O., Roncaglioni, M. C., Fortino, I., Nobili, A., & Sesti, G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110742 · Cited by 20 · see citing works
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 21 · see citing works
King, A., RAJPURA, J. R., Liang, Y. M., Paprocki, Y., & Uzoigwe, C. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2125259 · Cited by 18 · see citing works
Scheen, A. J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2354885 · Cited by 17 · see citing works
Alshaya, O. A., Korayem, G. B., Alghwainm, M., Alyami, W., Alotaibi, A., Yami, M. S. A., & Almohammed, O. A. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102054 · Cited by 14 · see citing works
Practical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & SKOLNIK, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 14 · see citing works
Li, C., Guo, S., Huo, J., Gao, Y., Yan, Y., & Zhao, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.987081 · Cited by 12 · see citing works
Lee, S. C., Pirikahu, S., Fritschi, L., Boyle, T., Schultz, C. J., Wylie, E. J., & Stone, J. (2023) · La radiologia medica · doi:10.1007/s11547-023-01611-y · Cited by 12 · see citing works
Lucero, K. S., Larkin, A. T., Zakharkin, S. O., Wysham, C., & Anderson, J. E. (2023) · JMIR Medical Education · doi:10.2196/48586 · Cited by 11 · see citing works
Nam, Y. H., Brensinger, C. M., Bilker, W. B., Flory, J., Leonard, C. E., & Hennessy, S. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2377 · Cited by 12 · see citing works
Verma, S., Sabbour, H. M., Alamuddin, N., Alawadi, F., Alkandari, H., Almahmeed, W. A., Assaad-Khalil, S. H., HADDAD, J. A., Lombard, L., Malik, R. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15011 · Cited by 11 · see citing works
Hou, W. C., Tuttle, K. R., Shen, W., Reikes, A., & Watanabe, J. H. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70108 · Cited by 10 · see citing works
Dril, E. V., Allison, M., & Schumacher, C. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100163 · Cited by 9 · see citing works
Weng, W., Kong, S. X., Ganguly, R., Hersloev, M., Brett, J., Hobbs, T. M., & Baeres, F. M. M. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.106 · Cited by 8 · see citing works
Cimellaro, A., Cavallo, M., Mungo, M., Suraci, E., Spagnolo, F., Addesi, D., Pintaudi, M., & Pintaudi, C. (2024) · Medicina · doi:10.3390/medicina60091542 · Cited by 10 · see citing works
Nishizawa, K., Tanaka, M., Sato, T., Gohda, T., Kamei, N., Murakoshi, M., Akiyama, Y., Kawaharata, W., Aida, H., Kouzu, H., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109146 · Cited by 8 · see citing works
Wu, J., Perez, A., & Sullivan, P. W. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.10.1029 · Cited by 7 · see citing works
Scheen, A. J. (2024) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2024.100197 · Cited by 7 · see citing works
Alhomoud, I. S., & Alamer, K. A. (2025) · Pharmaceuticals · doi:10.3390/ph19010009 · Cited by 6 · see citing works
King, A., Tan, X., Dhopeshwarkar, N., Bohn, R. L., Dea, K., Leonard, C. E., & de Havenon, A. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100922 · Cited by 6 · see citing works
Wharton, S., le Roux, C. W., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70263 · Cited by 5 · see citing works
Trueman, C., Shin, E. H., Donovan, A., McAdam‐Marx, C., & Coan, C. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.12.1275 · Cited by 5 · see citing works
Weng, W., Liang, Y. M., Brett, J., Hobbs, T. M., & Baeres, F. M. M. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107500 · Cited by 4 · see citing works
Arenas-León, J. L., Morales-Villegas, E., Cardona-Muñóz, E. G., Alcocer-Gamba, M. A., Ramirez-Contreras, J. P., Contreras-Sandoval, A. Y., & González-Gálvez, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01231-6 · Cited by 3 · see citing works
Παπάνας, Ν., Tsimihodimos, V., Katsiki, N., Doupis, J., Pagkalos, E. M., Nikas, N., Papakonstantopoulos, N., Karpouzos, G., & Tentolouris, N. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109087 · Cited by 3 · see citing works
Bashier, A. M., Agrawal, A., Dhanwal, D. K., Alawadi, F., Awada, G., Seifeldin, H., Sabbour, H. M., Aly, H., Abusahmin, H., Heshmat, H., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112030 · Cited by 3 · see citing works
Using the IMEDS distributed database for epidemiological studies in type 2 diabetes mellitus
HUANG, T.-Y. J., Rodriguez‐Watson, C., Wang, T., Calhoun, S. R., Marshall, J. H., Burk, J., Nam, Y. H., Mendelsohn, A. B., Jamal‐Allial, A., Greenlee, R. T., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002916 · Cited by 2 · see citing works
German, J., Huang, W. A., Brucker, A., Daniel, K., Halpern, D. J., Bhavsar, N. A., Hinz, E. M., Shannon, R., Pignone, M. P., Crowley, M. J., et al. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005546 · Cited by 1 · see citing works
Lussier, M. E., Gionfriddo, M. R., Graham, J., & Wright, E. A. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08435-6 · Cited by 1 · see citing works
Su, S., Wang, L., Tang, X., Zhao, N., Guan, C., Li, H., Liu, L., Liu, J., Che, H., Zhang, D., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-218364/v1
Darmon, P., Meyer, L., & Jubin, L. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.12.009
Moumen, A., Zraidi, M., Derrou, S., Benabdelfedil, Y., & Guendouz, F. E. (2023) · Clinical Diabetology · doi:10.5603/dk.a2023.0021
Chahine, B., Souheil, F. A., & Hanna, V. (2023) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2023.12.002
Salek, S., Sabbour, H. M., Alamuddin, N., Alawadi, F., Alkandari, H., Almahmeed, W. A., Assaad-Khalil, S. H., Ceyhan, E. M., HADDAD, J. A., Lombard, L., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1558515
2025 Clinical Practice Guidelines for Diabetes: Cardiovascular Risk Management
Kim, H. J. (2025) · Journal of Korean Diabetes · doi:10.4093/jkd.2025.26.3.164
Is There any Correlation Between Pulmonary and Coronary Involvement in Diabetic Patients?
Parham, M., Aghaali, M., Adeli, S. H., Bagheri, A. R., Sadeghi, M., & Asghari, A. (2025) · Intern J Endocrinol Metab · doi:10.5812/ijem-160600
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Agboghoroma, O., Heier, K., Ataç, Ö., Duncan, M. S., Kucharska‐Newton, A., & LACY, M. E. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005121
Mosenzon, O., Alguwaihes, A., Leon, J. L. A., Bayram, F., Darmon, P., Davis, T. M. E., Dieuzeide, G., Eriksen, K. T., Hong, T., Kaltoft, M. S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15064990
Oletu, H., Oladimeji, A. O., Okobi, E. K., Okwu, S., Kuye, A. A., Okobi, F., Osueni, A., Anya, O. O., Opoku, K. A., & Ogelebor, E. E. (2026) · Cureus · doi:10.7759/cureus.107319
Wang, S., DONG, B., & Shen, Z. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01915-y
- Authors
- Weng, W., Tian, Y., Kong, S. X., Ganguly, R., Hersloev, M., Brett, J., & Hobbs, T.
- Affiliations
- Novo Nordisk Inc. Plainsboro New Jersey
- Corresponding author
- Weng, Wayne
- Venue
- Endocrinology, Diabetes & Metabolism
- Publisher
- Wiley
- Published
- 2019-05-22
- Volume
- 2
- Issue
- 3
- Pages
- e00076-e00076
- ISSN
- 2398-9238 (ISSN-L)
- PMC
- PMC6613222
- OpenAlex
- W2944929227
- Cited by
- 65
- References
- 20
- Citations by year
- 2026: 3 · 2025: 15 · 2024: 11 · 2023: 12 · 2022: 11 · 2021: 7 · 2020: 4 · 2019: 2
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Endocrinology Diabetes & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, atherosclerotic cardiovascular disease, cardiovascular disease prevalence, GLP-1 receptor agonists, SGLT2 inhibitors, real-world data
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
